New drug YL202 takes on tough lung and breast cancers

NCT ID NCT05653752

First seen May 29, 2026 · Last updated Jun 16, 2026 · Updated 3 times

Summary

This early-stage study tests a new drug called YL202 in about 80 adults with advanced lung or breast cancer that has not responded to standard treatments. The main goals are to check the drug's safety and find the right dose. Researchers will also measure how the body processes the drug and whether tumors shrink.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • BRCR Global

    Plantation, Florida, 33322, United States

  • Fujian Cancer Hospital

    Fuzhou, Fujian, 350014, China

  • Hunan Cancer Hospital

    Changsha, Hunan, 410013, China

  • Jilin Provincial Cancer Hospital

    Changchun, Jilin, 130012, China

  • Karmanos Cancer Institute

    Detroit, Michigan, 48201, United States

  • Next Oncology-Dallas

    Irving, Texas, 75039, United States

  • Next Oncology-Virginia

    Fairfax, Virginia, 22031, United States

  • Summit Cancer Center

    Spokane Valley, Washington, 99216, United States

  • Taizhou Hospital of Zhejiang Province

    Taizhou, Zhejiang, 317099, China

  • The First Affiliated Hospital of Zhejiang University School of Medicine

    Hangzhou, Zhejiang, 310003, China

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • UT health east Texas HOPE Cancer Center

    Tyler, Texas, 75701, United States

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, 310022, China

Conditions

Explore the condition pages connected to this study.